Source: China – South China Morning PostChinese pharmaceutical companies that have developed a Covid-19 vaccine using advanced mRNA technology are planning to hold clinical trials in the southwestern provinces of Yunnan and Guangxi.The candidate vaccine, known as ARCoV and jointly developed by Walvax Biotechnology Co, Suzhou Abogen Biosciences and the Academy of Military Science, is set to become the first Chinese-developed mRNA vaccine to undergo phase 3 trials.The trial was registered in the Chinese government database on Wednesday…Read More